October 08, 2026 01:12 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
RBI shocks borrowers with first repo rate hike since 2023; rates raised to 5.50% | ‘Completely false’: Virat Kohli reacts to ₹5 crore claim over Premanand Maharaj visit | We’re watching it very closely: US urges Russia to share more information on plague situation | This isn’t about schools: Trump blames ‘mass migration’ and Islam for violent protests across France | ‘Crash axe’ blow fractured Smit Machchhar’s skull: Shocking details emerge from flydubai cockpit horror | ‘Vote thief’ Gyanesh Kumar: Rahul Gandhi climbs barricade, waves Tricolour during explosive INDIA bloc protest | ‘Crash axe’ blow fractured Smit Machchhar’s skull: Shocking details emerge from flydubai cockpit horror | ‘He should not have been flying’: JD Vance on Flydubai co-pilot | Israel was ready to shoot down Flydubai jet if it kept flying towards Tel Aviv: Reports | 'If law wasn't followed, we can undo it': Supreme Court's big warning on SIR process amid Gyanesh Kumar row
Covaxin

Brazil denies permission to import Bharat Biotech developed Covaxin

| @indiablooms | Apr 01, 2021, at 04:41 am

New Delhi/IBNS:  Brazil's health regulator has denied permission to import Covaxin, the coronavirus vaccine developed by India's indigenous firm Bharat Biotech.

According to reports, a Brazilian government gazette had said that Covaxin had been rejected "considering the non-compliance with the requirements of Good Manufacturing Practices for Medicines''.

In its response to the same, Bharat Biotech has told NDTV: ''The requirements pointed out during inspection will be fulfilled, the timelines for fulfilment is under discussion with the Brazil NRA and will be resolved soon.''

Bharat Biotech's indigenous vaccine-Covaxin-has been developed in collaboration with the Indian Council for Medical Research.

It was approved for emergency use by the  Drugs Controller General of India (DCGI) in January.

Covaxin has been declared to be an 81 per cent success during the Phase 3 clinical trials in India. 

Bharat Biotech said the vaccine is effective against the UK variant of the virus.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.